跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

安全信息

A7106

Sigma-Aldrich

Azelnidipine

≥98% (HPLC), powder

别名:

2-Amino-1,4-dihydro-6-methyl-4-(3 nitrophenyl)-3,5-pyridinedicarboxylic acid 3-[1-(diphenylmethyl)-3-azetidinyl] 5-(1-methylethyl) ester, CS-905, RS-9054

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C33H34N4O6
CAS号:
123524-52-7
分子量:
582.65
MDL编号:
MFCD00865803
UNSPSC代码:
12352200
PubChem化学物质编号:
329770914
NACRES:
NA.77

质量水平

100

方案

≥98% (HPLC)

表单

powder

溶解性

DMSO: >10 mg/mL

创始人

Daiichi-Sankyo

储存温度

room temp

SMILES字符串

CC(C)OC(=O)C1=C(C)NC(N)=C(C1c2cccc(c2)[N+]([O-])=O)C(=O)OC3CN(C3)C(c4ccccc4)c5ccccc5

InChI

1S/C33H34N4O6/c1-20(2)42-32(38)27-21(3)35-31(34)29(28(27)24-15-10-16-25(17-24)37(40)41)33(39)43-26-18-36(19-26)30(22-11-6-4-7-12-22)23-13-8-5-9-14-23/h4-17,20,26,28,30,35H,18-19,34H2,1-3H3

InChI key

ZKFQEACEUNWPMT-UHFFFAOYSA-N

应用

Azelnidipine is a novel dihydropyridine derivative, a L-type calcium channel blocker, and an antihypertensive. Acute administration of azelnidipine prevents a sudden drop of cardiac function after acute stress. Azelnidipine may have a protective role in inflammation associated with atherosclerosis.

生化/生理作用

Azelnidipine is a L-type calcium channel blocker; antihypertensive.
Azelnidipine, a novel dihydropyridine derivative, is a L-type calcium channel blocker and antihypertensive. Unlike other L-type calcium channel blockers, azelnidipine causes minimal stimulation of the sympathetic nervous system despite its significant depressor effect. Azelnidipine may have a protective role in inflammation in atherosclerosis.

特点和优势

This compound is featured on the Calcium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Daiichi-Sankyo. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形图

CorrosionExclamation mark
GHS05,GHS07

警示用语：

Danger

危险声明

H302,H318

危险分类

Acute Tox. 4 Oral - Eye Dam. 1

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

dust mask type N95 (US), Eyeshields, Gloves

法规信息

新产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000383566
0000383565
0000383565
0000383566
0000124727

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Hiroyuki Daikuhara et al.
Diabetes & vascular disease research, 9(4), 280-286 (2012-06-22)
Angiotensin II receptor blockers (ARB) are often co-administered with a calcium channel blocker (CCB) for treating hypertension. In this open-label randomised study, untreated diabetic hypertensive patients were randomised to receive either olmesartan 20 mg/day or candesartan 8 mg/day for 12
Takehisa Shimizu et al.
International heart journal, 53(5), 331-335 (2012-10-06)
Vascular calcification is an active and regulated process that is similar to bone formation. While calcium channel blockers (CCBs) have been shown to improve outcomes in atherosclerotic vascular disease, it remains unknown whether CCBs have an effect on the process
Hypertension in older adults: progress and limitations.
Michael W Rich
The American journal of medicine, 125(10), 949-950 (2012-08-21)
Takeshi Takami et al.
Vascular health and risk management, 7, 383-390 (2011-07-29)
The aim of this study was to compare the effects of olmesartan combined with either azelnidipine or amlodipine on central blood pressure (CBP) and left ventricular mass index (LVMI) in hypertensive patients. Patients with brachial systolic BP ≥ 140 mmHg
Ikuo Saito et al.
Journal of nephrology, 25(5), 699-708 (2011-10-25)
In the present investigation we extracted data on hypertensive patients with chronic kidney disease (CKD) who were enrolled in 3 studies - 2 studies of the angiotensin receptor blocker (ARB) olmesartan medoxomil (OLM), lasting 12 weeks and 2 years, respectively
查看所有相关文献

商品

Calcium Channels

We offers many products related to calcium channels for your research needs.

钙通道

我们提供多种与钙通道相关的产品以满足您的各类研究需求。

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门